echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > New coronavirus vaccine development! Evaluation of the combination of s-trimer candidate vaccine and pandemic vaccine adjuvant system by clover and GlaxoSmithKline

    New coronavirus vaccine development! Evaluation of the combination of s-trimer candidate vaccine and pandemic vaccine adjuvant system by clover and GlaxoSmithKline

    • Last Update: 2020-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The novel coronavirus biological pharmaceuticals limited (hereinafter referred to as "clover") has announced that it will launch research and development cooperation with GSK, a vaccine giant, to promote the research and development of its protein based new coronavirus vaccine "COVID-19 S- trimer" GSK will provide a vaccine adjuvant system for clover organisms to prevent disease pandemics in order to further evaluate the "s-trimer" in preclinical studies Clover bio is a global clinical trial biotechnology company headquartered in China, which is committed to the R & D and industrialization of innovative drugs and high-end bio similar drugs Novel coronavirus vaccine will be rapidly expanded by the cooperation, which is one of the largest cGMP biotech production capacity in China Novel coronavirus Thomas Breuer, a GSK vaccine chief medical officer, said: "we are proud to be able to help scientists in clover biology to make cutting-edge research This is also one of GSK's strategies, namely, to provide our adjuvant technology to those partners who have developed promising vaccines against new coronavirus Especially in the case of a pandemic, the use of adjuvants is particularly important, because it can reduce the amount of antigen required for each dose of vaccine, so that more people can get the protection of the vaccine " GSK is a leader in the development of innovative vaccines using different adjuvant systems Using adjuvants in some vaccines can enhance the immune response, resulting in stronger and more lasting immunity than using vaccines alone "We look forward to evaluating the efficacy of the GSK pandemic vaccine adjuvant system in combination with the 's-trimer' vaccine candidate," said Liang Guo, chief strategy officer and director of clover biology 's-trimer' is a patented technology of trimer tag © (protein trimerization) unique to clover, which can be used for specific recognition of serum antibody after rehabilitation of many patients with previous coronavirus infection Clover organisms are speeding up the development of 's-trimer' candidate vaccines to support the global fight against current and potential future coronavirus outbreaks " Mr Gong Dongyi, vice president of business expansion and strategy of clover, said: "we are honored to cooperate with GSK and are encouraged by the progress of our" s-trimer "vaccine development project We firmly believe that novel coronavirus vaccines should be accelerated through cooperation in an emergency "We welcome the regulatory authorities and interested academic or industry organizations to contact us to achieve the goal of conquering the epidemic." The novel coronavirus (SARS-CoV-2) novel coronavirus was discovered in late 2019, belonging to the envelope RNA virus family This family of viruses includes the Middle East respiratory syndrome (mers) virus and severe acute respiratory syndrome (SARS) virus, which can cause severe infection of human respiratory system The virus has caused novel coronavirus pneumonia, which has never been found in humans before As of February 21, 2020, the virus has infected more than 75000 people and killed more than 2100 people At present, the novel coronavirus epidemic has been listed as "public health emergencies of international concern" by WHO (WHO) The novel coronavirus is not currently available as a preventive vaccine After novel coronavirus genome nucleic acid sequences were discovered and published at the beginning of the year, clover organisms completed the synthesis of the S gene of the virus antigen at the first time, and constructed the recombinant protein vaccine gene expression vector of "S- trimer" by using its proprietary Trimer-Tag Technology (protein trimer) patented technology and gene recombination method Through gene transfer in mammalian cells to express and purify the covalent trimer fusion protein recombinant antigen "s-trimer", which is highly similar to the conformation of the natural surface antigen S protein of coronavirus Clover biopharmaceutical is a global biopharmaceutical company in the clinical trial stage, which is committed to the R & D and industrialization of innovative drugs, high-end biological similar drugs and recombinant RNA virus trimer vaccine Since 2016, clover has received more than 750 million yuan (more than 100 million US dollars) in total Clover uses its unique trimer tag © (protein trimerization) patent technology platform to develop novel biopharmaceutical and vaccine based on trimer functional structure; meanwhile, clover uses its own cGMP macromolecular biopharmaceutical production capacity to selectively develop high-end bioequivalent drugs Trimer tag © (protein trimerization) is an innovative platform for research and development of biopharmaceutical patent technology, which can construct covalent trimeric fusion protein The therapeutic targets and pathways of many important diseases depend on their trimerization, such as tumor necrosis factor superfamily (involved in exogenous apoptosis, immune co stimulation, inflammation, etc.) and envelope RNA virus antigen responsible for entering host cells Trimer tag © technology is used to construct trimeric fusion protein, which can effectively target the previously drug-free pathway S- trimer is novel coronavirus surface antigen S protein trimer subunit vaccine candidate Similar to other envelope RNA viruses such as HIV, respiratory syncytial virus and influenza virus, sars-cov-2 is also an RNA virus Its surface antigen S protein also has a trimer structure The virus binds with ACE2 receptor on the surface of host cell through its trimer antigen (s protein), so that it can enter human cells and become the main target antigen for vaccine development S-trimer is similar to the surface protein of natural trimer virus and can be expressed rapidly in mammalian cell culture.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.